Literature DB >> 14894598

The phasic variations in the ocular tension in primary glaucoma.

S DUKE-ELDER.   

Abstract

Entities:  

Keywords:  GLAUCOMA

Mesh:

Year:  1952        PMID: 14894598     DOI: 10.1016/0002-9394(52)91580-8

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


× No keyword cloud information.
  24 in total

1.  AQUEOUS FLOW MEASUREMENTS IN MAN BY THE PERILIMBAL SUCTION CUP TECHNIQUE. II. COMPARISONS IN CHRONIC SIMPLE GLAUCOMA BEFORE AND AFTER PILOCARPINE.

Authors:  M R CHANDLER
Journal:  Br J Ophthalmol       Date:  1964-08       Impact factor: 4.638

2.  [Current status of tonography].

Authors:  H O DEPNER
Journal:  Doc Ophthalmol       Date:  1958       Impact factor: 2.379

3.  Malignant glaucoma.

Authors:  H L BIRGE
Journal:  Trans Am Ophthalmol Soc       Date:  1956

4.  Comparative effects of cycloelectrolysis versus cyclodiathermy on the normal rabbit eye.

Authors:  L B SHEPPARD
Journal:  Trans Am Ophthalmol Soc       Date:  1956

5.  Prodromal malignant glaucoma.

Authors:  H L BIRGE
Journal:  Br J Ophthalmol       Date:  1957-06       Impact factor: 4.638

6.  Gonioscopic studies in congestive glaucoma.

Authors:  R SMITH
Journal:  Br J Ophthalmol       Date:  1954-03       Impact factor: 4.638

7.  Amyl nitrite test in primary glaucoma.

Authors:  G CRISTINI; N PAGLIARANI
Journal:  Br J Ophthalmol       Date:  1953-12       Impact factor: 4.638

8.  Stellate ganglion block in glaucoma.

Authors:  S J H MILLER
Journal:  Br J Ophthalmol       Date:  1953-02       Impact factor: 4.638

9.  Venous pressure and ocular tension; data concerning the diurnal variation of ocular tension.

Authors:  P WEINSTEIN; J FORGACS
Journal:  Br J Ophthalmol       Date:  1953-07       Impact factor: 4.638

10.  Diurnal IOP fluctuation: not an independent risk factor for glaucomatous visual field loss in high-risk ocular hypertension.

Authors:  Boel Bengtsson; Anders Heijl
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2005-03-09       Impact factor: 3.117

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.